Immunic gets a "positive surprise" from lead asset trial

By: TheNewswire.com

April 13, 2023 at 08:00 AM EDT

Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).

Vitt describes it as "wonderful data" that came as a "positive surprise."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

More News

MP Materials Stock Soared After Earnings—Here’s the Real Reason ↗

Today 11:09 EST

Via MarketBeat

Why Palantir Slide May Be a Setup for a Long-Term Opportunity ↗

Today 10:36 EST

Via MarketBeat

Attention Income Investors: This REIT Is on Sale ↗

Today 9:01 EST

Via MarketBeat

Rocket Lab Just Had Its First Real Crash—The Rebound Could Be Bigger ↗

Today 8:25 EST

Via MarketBeat

MarketBeat Week in Review – 11/17 - 11/21 ↗

Today 7:00 EST

Via MarketBeat

Recent Quotes

Symbol	Price	Change (%)
AMZN	220.69	+3.55 (1.63%)
AAPL	271.49	+5.24 (1.97%)
AMD	203.78	-2.24 (-1.09%)
BAC	51.56	+0.56 (1.10%)
GOOG	299.65	+9.67 (3.33%)
META	594.25	+5.10 (0.87%)
MSFT	472.12	-6.31 (-1.32%)
NVDA	178.88	-1.76 (-0.97%)
ORCL	198.76	-11.93 (-5.66%)
TSLA	391.09	-4.14 (-1.05%)

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.